Stock listing
Stockholm:BIOAB BioArctic AB Aktie
Home listing (Stockholm) of BioArctic AB
Follow BioArctic AB into a list and get an email when it puts out news.
Share price · OMXSTO:BIOA_B
300.60 SEK -3.80 (-1.2%)
Close on Nov 20, 2026
- Day range
- 300.00 – 304.80 SEKNov 20, 2026
- Volume
- 77,315 sharesNov 20, 2026
- Market cap
- 22.35B SEKAt the close on Nov 20, 2026 · price × 74.34M shares outstanding
- 52-week range
- 275.80 – 364.40 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 43.41M SEKMedian day 106,511 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:BRCTF | $30.10 USD | +0.105 (+0.4%) | 673 | $29.39 | $30.10 | $29.39 | $30.00 | Close on Nov 19, 2026 |
| Frankfurt:B9A | €26.26 EUR | -0.74 (-2.7%) | — | €26.58 | €26.58 | €26.26 | €27.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:BIOA_B · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 300.60 | -3.80 | -1.2% | 302.20 | 304.80 | 300.00 | 77,315 | |
| 304.40 | -0.40 | -0.1% | 304.20 | 310.20 | 303.60 | 75,615 | |
| 304.80 | -7.80 | -2.5% | 310.80 | 311.20 | 303.40 | 115,837 | |
| 312.60 | +2.60 | +0.8% | 309.80 | 314.00 | 309.60 | 68,001 | |
| 310.00 | -3.20 | -1.0% | 312.00 | 313.00 | 307.20 | 82,867 | |
| 313.20 | -0.80 | -0.3% | 313.00 | 315.60 | 310.40 | 50,536 | |
| 314.00 | +6.80 | +2.2% | 310.00 | 314.00 | 309.00 | 72,401 | |
| 307.20 | +2.00 | +0.7% | 304.00 | 307.20 | 296.40 | 96,472 | |
| 305.20 | -0.40 | -0.1% | 302.00 | 313.80 | 302.00 | 119,913 | |
| 305.60 | -5.80 | -1.9% | 312.00 | 312.00 | 302.00 | 91,429 | |
| 311.40 | +1.20 | +0.4% | 286.60 | 314.60 | 285.00 | 276,518 | |
| 310.20 | -7.00 | -2.2% | 317.40 | 318.00 | 310.20 | 94,196 | |
| 317.20 | -2.20 | -0.7% | 319.00 | 321.40 | 316.20 | 34,746 | |
| 319.40 | -0.80 | -0.2% | 320.60 | 325.80 | 318.00 | 156,970 | |
| 320.20 | +6.40 | +2.0% | 312.00 | 325.00 | 312.00 | 198,602 | |
| 313.80 | +5.60 | +1.8% | 308.00 | 313.80 | 304.60 | 72,607 | |
| 308.20 | +8.20 | +2.7% | 301.20 | 312.20 | 301.00 | 105,803 | |
| 300.00 | -1.40 | -0.5% | 300.00 | 302.80 | 296.40 | 77,805 | |
| 301.40 | +0.20 | +0.1% | 301.20 | 303.20 | 298.60 | 120,384 | |
| 301.20 | +1.20 | +0.4% | 298.60 | 303.20 | 297.20 | 48,856 | |
| 300.00 | +11.00 | +3.8% | 289.00 | 300.80 | 288.00 | 95,598 | |
| 289.00 | +1.60 | +0.6% | 287.20 | 290.40 | 283.20 | 104,527 | |
| 287.40 | -5.60 | -1.9% | 293.20 | 293.80 | 287.20 | 82,950 | |
| 293.00 | -1.00 | -0.3% | 294.00 | 294.40 | 285.00 | 145,152 | |
| 294.00 | +6.40 | +2.2% | 288.20 | 294.80 | 285.20 | 108,770 | |
| 287.60 | -10.60 | -3.6% | 297.80 | 298.60 | 286.40 | 121,809 | |
| 298.20 | +2.80 | +0.9% | 295.00 | 300.20 | 294.60 | 76,665 | |
| 295.40 | +5.00 | +1.7% | 290.40 | 298.80 | 290.40 | 63,548 | |
| 290.40 | -5.00 | -1.7% | 293.00 | 293.80 | 285.20 | 151,595 | |
| 295.40 | -6.80 | -2.3% | 296.80 | 300.40 | 292.20 | 174,546 | |
| 302.20 | +1.00 | +0.3% | 304.00 | 307.40 | 296.00 | 101,009 | |
| 301.20 | -4.00 | -1.3% | 305.00 | 309.20 | 300.80 | 68,861 | |
| 305.20 | -1.80 | -0.6% | 305.80 | 308.60 | 300.00 | 141,465 | |
| 307.00 | -3.40 | -1.1% | 312.40 | 312.40 | 304.60 | 116,389 | |
| 310.40 | +4.80 | +1.6% | 306.20 | 312.40 | 305.00 | 82,851 | |
| 305.60 | -3.20 | -1.0% | 308.80 | 314.80 | 305.00 | 163,377 | |
| 308.80 | -4.40 | -1.4% | 313.80 | 314.80 | 307.80 | 124,047 | |
| 313.20 | -5.20 | -1.6% | 319.00 | 320.80 | 313.20 | 136,470 | |
| 318.40 | -3.60 | -1.1% | 322.00 | 322.00 | 315.40 | 144,903 | |
| 322.00 | -5.20 | -1.6% | 328.60 | 332.80 | 322.00 | 77,947 | |
| 327.20 | +6.80 | +2.1% | 320.40 | 328.80 | 319.20 | 145,207 | |
| 320.40 | -0.60 | -0.2% | 321.40 | 323.20 | 318.60 | 102,370 | |
| 321.00 | -3.60 | -1.1% | 323.40 | 328.80 | 321.00 | 123,560 | |
| 324.60 | +6.60 | +2.1% | 317.80 | 324.60 | 317.40 | 61,799 | |
| 318.00 | +0.60 | +0.2% | 321.00 | 323.60 | 317.60 | 67,483 | |
| 317.40 | -8.00 | -2.5% | 323.20 | 325.80 | 317.40 | 100,030 | |
| 325.40 | +5.80 | +1.8% | 319.60 | 326.80 | 319.60 | 66,352 | |
| 319.60 | -7.20 | -2.2% | 326.80 | 328.80 | 319.60 | 107,055 | |
| 326.80 | -4.00 | -1.2% | 329.00 | 332.40 | 326.60 | 84,349 | |
| 330.80 | -0.40 | -0.1% | 332.00 | 333.20 | 327.00 | 85,328 | |
| 331.20 | +2.60 | +0.8% | 329.20 | 335.60 | 326.60 | 107,528 | |
| 328.60 | -5.40 | -1.6% | 331.00 | 333.40 | 328.20 | 65,248 | |
| 334.00 | -12.20 | -3.5% | 345.80 | 350.00 | 334.00 | 137,095 | |
| 346.20 | +20.00 | +6.1% | 330.20 | 349.00 | 330.20 | 402,604 | |
| 326.20 | +6.00 | +1.9% | 320.20 | 334.80 | 319.40 | 240,742 | |
| 320.20 | +1.80 | +0.6% | 318.40 | 324.00 | 314.80 | 124,105 | |
| 318.40 | -12.60 | -3.8% | 329.40 | 329.40 | 317.60 | 264,920 | |
| 331.00 | +5.60 | +1.7% | 327.80 | 337.60 | 327.20 | 304,957 | |
| 325.40 | +3.40 | +1.1% | 325.00 | 329.40 | 317.80 | 198,848 | |
| 322.00 | -23.00 | -6.7% | 348.00 | 360.00 | 314.60 | 928,957 | |
| 345.00 | +15.20 | +4.6% | 332.40 | 347.80 | 332.40 | 324,337 | |
| 329.80 | -5.80 | -1.7% | 332.40 | 337.80 | 329.80 | 157,912 | |
| 335.60 | -1.60 | -0.5% | 335.20 | 339.00 | 330.80 | 105,967 | |
| 337.20 | +6.00 | +1.8% | 332.00 | 340.80 | 331.80 | 135,597 |
- Ticker
- Stockholm:BIOA_B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Apr 21, 2026
BioArctic publishes the Annual Report and Sustainability Report for 2025
Latest earnings call · Aug 26, 2026
BioArctic (Stockholm:BIOA B) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 26, 2026
Q2 2026 Earnings Presentation
Earnings · 23 slides
Latest news
BioArctic publishes the Annual Report and Sustainability Report for 2025
Apr 21, 2026
Closed 321.60 (+1.2%) on Apr 22, 2026
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Mar 27, 2026
Closed 315.00 (-0.7%) on Mar 27, 2026
Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
Mar 11, 2026
Closed 318.00 (-0.9%) on Mar 11, 2026
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
Feb 27, 2026
Closed 302.40 (-2.1%) on Mar 2, 2026
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Feb 11, 2026
Closed 318.20 (-2.4%) on Feb 11, 2026
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Feb 9, 2026
Closed 324.40 (+5.7%) on Feb 9, 2026
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Feb 6, 2026
Closed 306.80 (+0.6%) on Feb 6, 2026
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Jan 25, 2026
Closed 321.20 (+3.3%) on Jan 26, 2026
BLA for subcutaneous formulation of Leqembi® accepted in China
Jan 6, 2026
Closed 329.00 (+6.3%) on Jan 7, 2026
Leqembi included in China's commercial insurance innovative drug list
Dec 8, 2025
Closed 315.40 (-0.8%) on Dec 9, 2025
BioArctic AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 30 in all · newest Apr 21, 2026 · oldest 2025
- Calls
- 14 calls with a replay · 14 with a transcript · latest Aug 26, 2026
- Decks
- 27 decks · latest Aug 26, 2026
Where BioArctic AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BIOAB · Home listing · This page | Stockholm | Sweden | SEK |
| gettex:B9A | gettex | Germany | EUR |
| LSIN:0RV2 | LSIN | United Kingdom | SEK |
| Aquis:BIOABS | Aquis | United Kingdom | SEK |
| OTC:BRCTF | OTC | United States | USD |
| LS Exchange:A2H5GS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2H5GS | Lang & Schwarz | Germany | EUR |
| Tradegate:B9A | Tradegate | Germany | EUR |
| Frankfurt:B9A | Frankfurt | Germany | EUR |
| Hamburg:B9A | Hamburg | Germany | EUR |
| Aquis:BIOABS | Aquis | United Kingdom | SEK |
| Dusseldorf:B9A | Dusseldorf | Germany | EUR |
| Munich:B9A | Munich | Germany | EUR |
| Stuttgart:B9A | Stuttgart | Germany | EUR |
| Turquoise:BIOABS | Turquoise | United Kingdom | SEK |
Valuation
P/E 212× against a median of 3.4×: the highest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 20.45B SEK
- P/E
- 212×
- EV/sales
- 20.4×
- EV/EBITDA
- 90.0×
- Price/book
- 11.1×
- Gross margin
- 93.2%
- Operating margin
- 21.4%
- Net margin
- 10.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.01B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.70B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.24B | US$2.02B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.8M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Regencell Bioscience Holdings Limited · NASDAQ:RGC | US$2.07B | US$2.06B | n/a | n/a | n/a | 155× | n/a | 0.0× | 1.57 |
| Median of the others | US$2.20B | US$1.71B | 3.4× | 12.8× | 3.8× | −263.4% | 0.0× | 1.41 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 314.00 SEK · Analysts' mean
- EPS, year to Dec 2026
- 5.75 · 2 analysts
- Revenue, year to Dec 2026
- 1.52B · 3 analysts
Events
- Next results
- Nov 25, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| BioArctic (Stockholm:BIOA B) Q2 2026 Earnings Call | Wed, Aug 26, 2026 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2026 Earnings Call | Wed, May 20, 2026 · 1:00 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q4 2025 Earnings Call | Wed, Feb 18, 2026 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2025 Earnings Call | Thu, Aug 28, 2025 · 4:00 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2025 Earnings Call | Wed, May 21, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2024 Earnings Call | Thu, Aug 29, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2024 Earnings Call | Fri, May 17, 2024 · 3:30 AM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| BioArctic (Stockholm:BIOA B) Q4 2023 Earnings Call | Wed, Feb 14, 2024 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q2 2023 Earnings Call | Wed, Jul 12, 2023 · 3:30 AM ET | Replay |
| BioArctic (Stockholm:BIOA B) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 3:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 26, 2026 · Before open | −6.7% |
| Q1 2026 | May 20, 2026 · Before open | +1.5% |
| Q4 2025 | Feb 18, 2026 · Before open | +12.4% |
| Q3 2025 | Nov 13, 2025 · Before open | +7.2% |
| Q2 2025 | Aug 28, 2025 · Before open | +11.8% |
| Q1 2025 | May 21, 2025 · Before open | +11.0% |
| Q4 2024 | Feb 13, 2025 · Before open | +1.8% |
| Q3 2024 | Nov 14, 2024 · Before open | +29.9% |
| Q2 2024 | Aug 29, 2024 · Before open | +8.5% |
| Q1 2024 | May 17, 2024 · Before open | −0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 14, 2024 · Before open | +8.2% |
| Q3 2023 | Nov 8, 2023 · Before open | −1.8% |
| Q2 2023 | Jul 12, 2023 · Before open | +0.5% |
| Q1 2023 | Apr 27, 2023 · After close | +4.1% |
| Q4 2022 | Feb 3, 2023 · Before open | −1.8% |
| Q3 2022 | Oct 20, 2022 · Before open | +4.6% |
| Q2 2022 | Jul 12, 2022 · Before open | −3.1% |
| Q1 2022 | Apr 28, 2022 · Before open | −6.5% |
| Q4 2021 | Feb 3, 2022 · Before open | −1.3% |
| Q3 2021 | Oct 21, 2021 · Before open | −1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Aug 26, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 26 slides | May 20, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 18, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 27 slides | Nov 13, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 29 slides | Aug 28, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 23 slides | May 21, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 19 slides | Feb 13, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 23 slides | Nov 14, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 22 slides | Aug 29, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 22 slides | May 17, 2024 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2023 Earnings Presentation | Earnings | 19 slides | Feb 14, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 20 slides | Nov 8, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 14 slides | Jul 12, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 22 slides | Apr 27, 2023 |
| Q4 2022 Earnings Presentation | Earnings | 17 slides | Feb 3, 2023 |
| Clinical Trials on Alzheimer's Disease (CTAD) 2022 | Conference | 74 slides | Dec 2, 2022 |
| Technical Presentation (August 2022) | Technical | 9 slides | Aug 4, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 17 slides | Jul 12, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 18 slides | Apr 28, 2022 |
| FY2021 Earnings Presentation | Earnings | 21 slides | Feb 3, 2022 |
| Q2 2021 Earnings Presentation | Earnings | 16 slides | Jul 9, 2021 |
| Q1 2021 Earnings Presentation | Earnings | 16 slides | Apr 21, 2021 |
| FY2020 Earnings Presentation | Earnings | 16 slides | Feb 4, 2021 |
| Q3 2020 Earnings Presentation | Earnings | 18 slides | Oct 14, 2020 |
| Q2 2020 Earnings Presentation | Earnings | 18 slides | Jul 10, 2020 |
| Shareholder Meeting (2020) | Shareholder meeting | 6 slides | 2020 |
| Shareholder Meeting (May 2019) | Shareholder meeting | 10 slides | May 9, 2019 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.00B | 257.4M | 616.0M | 228.3M | 23.1M | 62.3M | 281.8M | 714.0M | 140.7M | 105.6M |
| Cost of revenue | 59.2M | 27.0M | 15.0M | 74.3M | 55.1M | 50.2M | 72.4M | 145.4M | 266.0K | 238.0K |
| Gross profit | 1.94B | 230.4M | 601.0M | 154.0M | -31.9M | 12.1M | 209.4M | 568.6M | 140.4M | 105.4M |
| Research and development | 376.9M | 311.1M | 172.1M | 74.3M | 55.1M | 50.2M | 72.4M | 145.4M | 101.6M | 53.7M |
| Selling, general and administrative | 115.7M | 93.4M | 128.5M | 115.7M | 24.9M | 23.4M | 31.2M | 31.9M | 31.5M | 14.5M |
| Operating income | 1.26B | -228.5M | 252.6M | -10.2M | -139.7M | -82.3M | 112.5M | 488.8M | 19.3M | 74.6M |
| Depreciation and amortization | 12.8M | 10.7M | 18.4M | 14.6M | 13.1M | 10.9M | 9.20M | 2.06M | 1.99M | 1.56M |
| EBITDA | 1.27B | -217.8M | 271.1M | 4.47M | -126.6M | -71.4M | 121.7M | 490.9M | 21.3M | 76.2M |
| Interest expense | 37.9M | 1.85M | 10.4M | 2.12M | 984.0K | 1.10M | 1.19M | 1.37M | 647.0K | 5.00K |
| Income before tax | 1.26B | -189.5M | 276.5M | -11.2M | -140.5M | -86.7M | 113.0M | 489.6M | 19.7M | 74.1M |
| Income tax | 233.3M | -12.4M | 47.2M | 11.0K | -20.7M | -18.2M | 24.5M | 108.0M | 4.53M | 16.6M |
| Net income | 1.02B | -177.1M | 229.2M | -11.2M | -119.8M | -68.5M | 88.5M | 381.6M | 15.2M | 57.6M |
| Earnings per share, basic | 1,155,000.00 | -200,000.00 | 260,000.00 | -0.13 | -1.36 | -0.78 | 1.00 | 4.33 | 0.17 | 0.65 |
| Earnings per share, diluted | 1,152,000.00 | -200,000.00 | 259,000.00 | -13.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.04B | 512.9M | 611.6M | 805.4M | 848.4M | 999.9M | 1.11B | 917.3M | 1.11B | 692.5M |
| Short-term investments | 1.15B | 266.0M | 500.0M | |||||||
| Receivables | 121.6M | 71.2M | 223.0K | 0 | 2.84M | 5.60M | 28.7M | 462.3M | 17.3M | 634.0K |
| Inventory | -223.0K | 7.50M | 1 | 2.94M | -462.3M | 2.81M | -634.0K | |||
| Current assets | 2.49B | 1.01B | 1.15B | 820.8M | 861.8M | 1.01B | 1.14B | 1.38B | 1.13B | 699.5M |
| Property, plant and equipment | 36.9M | 39.5M | 23.5M | 23.5M | 17.0M | 39.9M | 37.1M | 9.29M | 7.09M | 5.64M |
| Total assets | 2.58B | 1.11B | 1.19B | 858.3M | 897.7M | 1.05B | 1.18B | 1.39B | 1.14B | 708.0M |
| Accounts payable | 23.9M | 50.5M | 29.9M | 21.5M | 11.8M | 14.3M | 8.22M | 14.8M | 7.59M | 11.7M |
| Current liabilities | 520.8M | 175.7M | 125.0M | 70.9M | 101.3M | 108.7M | 149.2M | 342.8M | 498.9M | 643.1M |
| Total debt | 44.1M | 54.2M | 4.98M | 10.0M | 15.9M | 20.8M | 27.4M | |||
| Total liabilities | 608.1M | 216.7M | 139.5M | 72.1M | 109.1M | 143.0M | 208.8M | 375.3M | 504.3M | 647.2M |
| Shareholders' equity | 1.97B | 894.9M | 1.05B | 786.2M | 788.7M | 907.3M | 974.5M | 1.02B | 636.1M | 60.8M |
| Shares outstanding | 88.7M | 88.5M | 88.5M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M | 88.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.43B | -316.3M | 309.7M | -31.6M | -140.5M | -92.3M | 327.2M | -200.1M | -135.3M | 675.1M |
| Capital spending | -10.2M | -26.6M | -7.44M | -12.7M | -4.39M | -12.5M | -3.26M | -4.25M | -3.45M | -2.97M |
| Free cash flow | 1.42B | -343.0M | 302.3M | -44.4M | -144.8M | -104.8M | 323.9M | -204.3M | -138.8M | 672.2M |
| Cash from investing | -894.6M | 205.6M | -507.5M | -12.8M | -4.41M | -12.5M | -3.27M | -3.08M | -2.81M | -2.97M |
| Cash from financing | 26.9M | 5.69M | 14.1M | -2.81M | -7.39M | -6.60M | -138.5M | -138.5M | 560.2M | -105.1M |
| Dividends paid | -26.0M | -6.02M | -15.0M | -5.99M | 0 | 0 | -132.1M | -132.1M | -132.1M | -105.1M |
| Share buybacks | 6.02M | 15.0M | 5.99M | 0 | 560.2M | |||||
| Change in cash | 563.3M | -105.0B | -183.7B | -47.2B | -152.3M | -112.8M | 195.5M | -193.1M | 417.8M | 578.7M |
Cap table
Built by 6ix from BioArctic AB Class B’s releases
- Common shares
- 74,344,689
- Fully diluted
- 74,344,689
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 74,344,689 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 74,344,689 |
Log in to ask 6ix AI your own questions about BioArctic AB.